Research Topics

Genomes and Genes

Species

Miguel Martin

Summary

Affiliation: Hospital Universitario San Carlos
Country: Spain

Publications

  1. Echavarria I, López Tarruella S, Picornell A, Garcia Saenz J, Jerez Y, Hoadley K, et al. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res. 2018;24:1845-1852 pubmed publisher
    ..i>Clin Cancer Res; 24(8); 1845-52. ©2018 AACR. ..
  2. Ruiz Borrego M, Jiménez B, Antolín S, García Sáenz J, Corral J, Jerez Y, et al. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. Invest New Drugs. 2018;: pubmed publisher
    ..EudraCT study number: 2013-001750-96. Study GEICAM/2012-12. EudraCT study number: 2013-001750-96. Study GEICAM/2012-12. ClinicalTrials.gov: NCT02027376. ..
  3. Martin M, de la Torre Montero J, López Tarruella S, Pinilla K, Casado A, Fernandez S, et al. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat. 2018;171:627-634 pubmed publisher
    ..This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762. ..
  4. Ethier J, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, et al. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. Eur J Cancer. 2018;94:199-205 pubmed publisher
    ..EudraCT: 2005-003108-12 (retrospectively registered 28/06/2005). CLINICALTRIALS. NCT00129922 (retrospectively registered 10/08/2005). ..
  5. Martin M, Prat A, Rodriguez Lescure A, Caballero R, Ebbert M, Munarriz B, et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013;138:457-66 pubmed publisher
    ..109). The PAM50 proliferation score identifies a subset of patients with a low proliferation status that may derive a larger benefit from weekly paclitaxel. ..
  6. Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015;33:1045-52 pubmed publisher
    ..The addition of bevacizumab to ET in first-line treatment failed to produce a statistically significant increase in PFS or OS in women with HER2-negative/hormone receptor-positive advanced breast cancer. ..
  7. Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez Lescure Ã, Muñoz Mateu M, et al. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. J Clin Oncol. 2015;33:3788-95 pubmed publisher
    ..Toxicity profiles differed substantially across arms. ..
  8. Martín M. nab-Paclitaxel dose and schedule in breast cancer. Breast Cancer Res. 2015;17:81 pubmed publisher
    ..The growing number of nab-paclitaxel trials in breast cancer will lead to greater refinements in tailoring therapy to patients based on their individual disease and patient characteristics. ..
  9. Martin M, Rodriguez Lescure A, Ruiz A, Alba E, Calvo L, Ruiz Borrego M, et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat. 2010;123:149-57 pubmed publisher
    ..The molecular-defined subgroup of TN was clearly predictive of better response to treatment with FEC-P. Luminal A patients had the best prognosis and also have a better outcome with weekly paclitaxel. ..

More Information

Publications21

  1. Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17:56 pubmed publisher
    ..The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+ HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy. ..
  2. Martín M, Martínez N, Ramos M, Calvo L, Lluch A, Zamora P, et al. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. Oncologist. 2015;20:111-2 pubmed publisher
    ..Further investigation is required to improve HFS. Polymorphisms in several genes might contribute to interindividual differences in response to capecitabine. ..
  3. Martin M, Rodriguez Lescure A, Ruiz A, Alba E, Calvo L, Ruiz Borrego M, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100:805-14 pubmed publisher
    ..Among patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy. ..
  4. Martin M, Seguí M, Anton A, Ruiz A, Ramos M, Adrover E, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363:2200-10 pubmed publisher
    ..As compared with adjuvant FAC, adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer. (Funded by GEICAM and Sanofi-Aventis; ClinicalTrials.gov number, NCT00121992.). ..
  5. Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016;56:85-92 pubmed publisher
    ..NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials. ..
  6. Martin M, Brase J, Ruiz A, Prat A, Kronenwett R, Calvo L, et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Res Treat. 2016;156:81-9 pubmed publisher
    ..ROR and EP can reliably predict risk of distant metastasis in node-positive ER+/HER2- BC patients treated with chemotherapy and ET. Addition of clinical parameters into risk scores improves their prognostic ability. ..
  7. Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, et al. First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast. 2018;38:144-149 pubmed publisher
    ..The superiority of fulvestrant 500 mg over fulvestrant 250 mg in patients with LA/MBC in CONFIRM was consistent in both the first- and second-line settings for PFS, and numerically greater in both settings for OS. ..
  8. Martin M, Fumoleau P, Dewar J, Albanell J, Limentani S, Campone M, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann Oncol. 2016;27:1249-56 pubmed publisher
    ..T-DM1 combined with docetaxel ± pertuzumab appeared efficacious in MBC or LABC; however, nearly half of patients experienced AEs requiring dose reductions with these T-DM1 combinations. NCT00934856. ..
  9. Martin M, López Tarruella S, Gilarranz Y. Endocrine therapy for hormone treatment-naïve advanced breast cancer. Breast. 2016;28:161-6 pubmed publisher
  10. Martin M, Chacón J, Anton A, Plazaola A, García Martínez E, Seguí M, et al. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. Oncologist. 2017;22:1301-1308 pubmed publisher
    ..Findings point to an encouraging single-agent neoadjuvant treatment with low toxicity, which warrants future research and development. ..
  11. Martin M, Holmes F, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688-1700 pubmed publisher
    ..An analysis of overall survival is planned after 248 events. Wyeth, Pfizer, and Puma Biotechnology. ..
  12. request reprint
    Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18:4841-9 pubmed
    ..We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL)...